Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor.

The prevalence of BRAF mutation has been reported in between 38% and 48% of melanoma patients, based on mainly Stage III or metastatic melanoma, however, information based on population-based studies is scarce. We performed a population-based retrospective cohort study to determine the prevalence of the BRAF mutation in patients diagnosed with in situ and infiltrating cutaneous malignant melanoma in the province of Girona between 2009 and 2011. Using the database of the Girona Cancer Registry, we performed BRAF mutation analysis based on paraffin-embedded tissue. This data was then correlated with other known clinical and histological prognostic factors for survival. We found 286 incident cases of cutaneous melanoma in the Girona Cancer Registry database. Excluding missing cases, BRAF-mutated patients constituted 38.9% of "in situ" melanoma cases and 53.8% of invasive melanoma cases. Five-year relative survival was not statistically different between BRAF-mutated patients (93.6%; 95% CI: 87.1-100.5) and non-mutated patients (84.3%, 95% CI: 75.3-94.8). Only stage was significant as a prognostic factor for survival based on multivariate analysis. From our population-based study, we conclude that BRAF mutation is not an independent prognostic factor for melanoma survival.

[Non-melanoma skin cancer: incidence time trends analysis in Girona, Spain, 1994-2007]. / Cáncer cutáneo distinto de melanoma: tendencia de la incidencia poblacional en Girona, 1994-2007.

BACKGROUND AND OBJECTIVE: We aimed to assess the population-based incidence trends of non-melanoma skin cancer (NMSC): squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). PATIENTS AND METHOD: From January 1994 to December 2007, 9,247 patients diagnosed with NMSC were recruited in the population-based Cancer Registry of Girona. Incidence rates were calculated with age-adjusted according to the Word standard population (WASR) by a direct method and reported as number of new cases per 100,000 person-year. To evaluate incidence trends by age group we used specific rates for these groups (45-64, > 64 years). We excluded patients younger than 45 years. Joinpoint method was used to estimate the average annual percentage change (AAPC) for the whole study period according to histologic and age groups. RESULTS: Age-adjusted incidence was 55.74 per 10(5) person-year; it was higher in males (67.13) than in females (46.9). Age-adjusted incidence for BCC was higher compared with the incidence for SCC (44.56 and 11.18 respectively). Age-adjusted incidence rate for NMSC for both sexes increased from 48.53 (1994-95) to 60.54 (2004-05) with an AAPC of 2.30%, which was higher in females (2.65%) than in males (1.99%). CONCLUSIONS: There has been a significant increase in the incidence of NMSC in our area, particularly evident for SCC, and it is more important in patients older than 64 years and in females.

[Merkel cell cancer of the skin: population-based incidence and survival, 1995-2005]. / Carcinoma de células de Merkel cutáneo: incidencia y supervivencia poblacional, 1995-2005.

BACKGROUND AND OBJECTIVE: We aimed to assess the population-based incidence and survival of primary Merkel cell carcinoma. MATERIAL AND METHOD: From January 1995 to December 2005, 19 patients diagnosed with primary Merkel cell carcinoma were recruited in the population-based Cancer Registry of Girona. RESULTS: The age-adjusted incidence was 1,3 per 10(6) person-year; higher in males (1,5) than in females (1,1). Cases occurred mostly in people older than 65 years (94,7%), especially involving the head (79%). CONCLUSIONS: To our knowledge, this study is the first to define the incidence and survival of Merkel cell carcinoma in Europe. The age-adjusted incidence of primary Merkel cell carcinoma in our area is similar than the age-adjusted incidence of the 2000 US standard population.

Carcinoma de células de Merkel cutáneo: incidencia y supervivencia poblacional, 1995–2005 / Merkel cell cancer of the skin: population-based incidence and survival, 1995–2005

Fundamento y objetivo: Conocer la incidencia y supervivencia poblacional del carcinoma de células de Merkel. Material y método: De enero de 1995 a diciembre de 2005 se registraron un total de 19 casos de carcinoma primario de células de Merkel en la población cubierta por el Registro de Cáncer Poblacional de Girona. Resultados: La incidencia ajustada por edad a la población estándar mundial fue de 1,3 casos por 106 personas-año, siendo superior en varones (1,5) que en mujeres (1,1), con predominio de los casos en mayores de 65 años (94,7%). La región anatómica de la cabeza fue la localización afectada con mayor frecuencia (79%). Conclusiones: Se trata del primer trabajo, en nuestro conocimiento, que estima la incidencia y la supervivencia poblacional del carcinoma de células de Merkel en Europa. La incidencia observada en nuestra área es similar a la incidencia observada en EE. UU (AU)

Background and objective: We aimed to assess the population-based incidence and survival of primary Merkel cell carcinoma. Material and method: From January 1995 to December 2005, 19 patients diagnosed with primary Merkel cell carcinoma were recruited in the population-based Cancer Registry of Girona. Results: The age-adjusted incidence was 1,3 per 106 person-year; higher in males (1,5) than in females (1,1). Cases occurred mostly in people older than 65 years (94,7%), especially involving the head (79%). Conclusions: To our knowledge, this study is the first to define the incidence and survival of Merkel cell carcinoma in Europe. The age-adjusted incidence of primary Merkel cell carcinoma in our area is similar than the age-adjusted incidence of the 2000 US standard population (AU)

Linfomas primarios cutáneos: incidencia y supervivencia poblacional, 1994-2004 / No disponible

No disponible